Robert W. Duggan & Associates

Robert W. Duggan & Associates is the private investment vehicle and family office of billionaire biotech entrepreneur Robert W. Duggan. The firm is most notable for its strategic leadership and majority stake in Pharmacyclics, which was acquired by AbbVie for $21 billion following the success of the blockbuster oncology drug Imbruvica. Currently, the entity serves as the primary holding vehicle for Duggan's significant ownership interests and executive roles in companies such as Summit Therapeutics and Pulse Biosciences. The firm focuses on high-conviction investments in life science companies developing disruptive therapies in oncology, infectious diseases, and medical technology. It is characterized by an active management style, often placing Duggan in key executive or board positions to oversee clinical development and commercialization strategies.